View all results
Swiss Biotech Report
Mission and services
Leave a review
NOTCH Positive Cancers (Solid Tumors and Hematological Malignancies)
Cellestia Biotech AG
You may also be interested in
MV-002 is an orally available modified live biotherapeutic converting the majority of solid tumor patients refractory to immune checkpoint blockade (ICB) to responders. MV002 in combination with different ICB significantly increases the percentage of responding animals (e.g. anti-PD-L1 monotherapy, from 25-30% to 70/80% with MV-002 in translational models of solid tumor).
MV BioTherapeutics SA
4D Lifetest Lung Dx, 4D Lifetest Breast Dx, 4D Lifetest Colon Dx
4D Lifetest Lung Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of lung cancer for symptomatic patients in combination with other lung cancer specific diagnostics. 4D Lifetest Breast Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of breast cancer for symptomatic patients in combination with other breat cancer specific diagnostics. 4D Lifetest Colon Dx is used as a verification assay to increase the overall sensitivity for the diagnosis of colon cancer for symptomatic patients in combination with other colon cancer specific diagnostics.
4D Lifetec AG
TOP-N53, TOP-V122, TOP-M119 and TOP-N44
TOPADUR has discovered and developed new dual-acting drugs that target the cGMP-Enzyme Regulation System to stimulate microcirculation, enable tissue regeneration, and avoid local oxygen deficiency. Based on our key invention we have developed an attractive portfolio of drug candidates to treat aging-related diseases as chronic wounds, glaucoma, colorectal cancer, hair loss and skin aging.
Phase I started
TOPADUR Pharma AG
View all results
Find out more.